This study is a prospective, open and non-interventionalclinical study. It is planned to enroll 240 patients with iron deficiency anemia caused by uterine fibroids and adenomyosis in 4 centers of obstetrics and gynecology in China.All patients who met the inclusion criteria and agreed to participate in the study received routine blood tests, serum ferritin, serum iron and total iron binding ability tests and clinical follow-up. All patients were given 15ml oral protein iron succinate solution (Fiapril) in the morning and evening each day.Blood routine examinations (Hb, reticulocytes, RBC, HCT), serum ferritin, serum iron and total iron binding ability were detected at the 1st, 4th, 8th and 12th weeks of the study to observe the change trend of their own indicators.Symptom self-assessment tables were collected to assess the improvement rate of clinical symptoms including dizziness, fatigue, chest tightness and palpitations, and to record the incidence of adverse reactions (mainly gastrointestinal reactions).
This project is a prospective, open, non-interventionalclinical study. It is planned to enroll 240 patients with iron deficiency anemia caused by uterine fibroids and adenomyosis in the department of obstetrics and gynecology in 4 centers nationwide. All patients who met the inclusion criteria and agreed to participate in the study received routine blood tests, serum ferritin, serum iron and total iron binding ability tests and clinical follow-up. All patients were given 15ml Iron Proteinsuccinylate Oral Solution in the morning and evening each day. Evaluation of therapeutic efficacy: Blood routine examinations (Hb, reticulocytic cell, RBC, HCT), serum ferritin, serum iron and total iron binding force were collected at week 1, 4, 8 and 12 of the study. Patients self-rated clinical symptoms such as dizziness, fatigue, chest tightness and palpitations.To evaluate laboratory measures of improvement and response rate (symptom relief) in patients with uterine fibroids and adenomyosis induced iron deficiency anemia presented to the department of obstetrics and gynecology, and the incidence of complications during the study period。 Patients with iron deficiency anemia caused by uterine fibroids and adenomyosis in the department of obstetrics and gynecology included in this study group were followed up for 12 weeks.The results of patients' self-assessed symptoms, including blood routine (Hb, reticulocyte, RBC, HCT), serum ferritin, serum iron, total iron binding ability and other indicators, as well as the occurrence of complications at baseline level and during short-term follow-up of 12 weeks, will be collected to determine the clinical outcomes of patients through hospital follow-up.
Study Type
OBSERVATIONAL
Enrollment
240
HB
The levels of hemoglobin in 1 week of treatment.
Time frame: The first week of treatment
SF
The levels of serum ferritin in 1 week of treatment.
Time frame: The first week of treatment
HB
The levels of hemoglobin in 4 week of treatment.
Time frame: The fourth week of treatment
SF
The levels of serum ferritin in 4 week of treatment.
Time frame: The fourth week of treatment
HB
The levels of hemoglobin in 8 week of treatment.
Time frame: Eight weeks after treatment
SF
The levels of serum ferritin in 8 week of treatment.
Time frame: Eight weeks after treatment
HB
The levels of hemoglobin in 12 weeks of treatment.
Time frame: Twelve weeks after treatment
SF
The levels of serum ferritin in 12 weeks of treatment.
Time frame: Twelve weeks after treatment
RBC
The levels of red blood cell in 1week of treatment.
Time frame: 1 weeks after treatment.
HCT
The levels of hematocrit in 1week of treatment.
Time frame: 1 weeks after treatment.
SI
The levels of free iron in 1week of treatment.
Time frame: 1 weeks after treatment.
RBC
The levels of red blood cell in 4weeks of treatment.
Time frame: 4 weeks after treatment.
HCT
The levels of hematocrit in 4weeks of treatment.
Time frame: 4 weeks after treatment.
SI
The levels of free iron in 4 weeks of treatment.
Time frame: 4 weeks after treatment.
RBC
The levels of red blood cell in 8 weeks of treatment.
Time frame: 8 weeks after treatment.
HCT
The levels of hematocrit in 8 weeks of treatment.
Time frame: 8 weeks after treatment.
SI
The levels of free iron in 8 weeks of treatment.
Time frame: 8 weeks after treatment.
RBC
The levels of red blood cell in 12 weeks of treatment.
Time frame: 12 weeks after treatment.
HCT
The levels of hematocrit in 12 weeks of treatment.
Time frame: 12 weeks after treatment.
SI
The levels of free iron in 12 weeks of treatment.
Time frame: 12 weeks after treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.